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Available online 30        Ma  y  2019Background: Studies that evaluate larger numbers of protein biomarkers in patients with coronarymicrovascular
dysfunction (CMD) have not previously been performed, and very little is known concerning the pathogenetic
mechanisms leading to CMD.
Our objectivewas to analyze associations between a broad cardiovascular disease (CVD) protein biomarker assay
and CMD, and further explore internal biomarker relations in order to identify possible targets for future
treatment interventions.
Methods: In 174 women with angina pectoris and no significant obstructive coronary artery disease (b50%
stenosis on invasive coronary angiography), CMD was assessed by transthoracic Doppler echocardiography
measuring coronary flow velocity reserve (CFVR). Blood samples were analyzed with a CVD proteomic panel
encompassing 92 biomarkers. The relation between biomarkers and CFVR was evaluated by regression
analysis, and possible interrelations between significant biomarkers were investigated by principal component
analysis (PCA).
Results:Median age (SD) was 64 years (9.8), median CFVR (IQR) was 2.3 (1.9–2.7), and 28% of patients had
CFVR b 2.0. Eighteen biomarkers were significantly correlated with CFVR. In PCA, 8 of the biomarkers
significantly related to CFVR showed high loadings on principal component 1 (PC1). The component scores
of PC1 were significantly related to CFVR (p = 0.002). The majority of the 8 interrelated PC1 biomarkers
were related to the pro-inflammatory TNF-α – IL-6 – CRP pathway.
Conclusion: Eighteen protein biomarkers were significantly associated with CMD. Eight biomarkers were
interrelated in PCA, and share connection with pro-inflammatory pathways, highlighting a possible
important role of inflammation in CMD.k (J. Sch
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Coronary microvascular dysfunction
Biomarkers
Principal component analysis1. Introduction
Coronary microvascular dysfunction (CMD) is the possible cause
of symptoms in a substantial proportion of patients with angina
and no obstructive coronary artery disease (CAD) [1]. Development
of novel simple diagnostic tests and effective treatment in this
large patient group is hindered by an incomplete understanding
of the pathogenetic process leading to CMD. Compared with
macrovascular cardiovascular disease (CVD), protein biomarker
studies in CMD have been scarce and a recent CMD White Paper
called for more studies of functionally related proteins, which may
guide targeted intervention in CMD [2].roder).
an open access article under
 at BS - University of Copen
r uses without permission. CWe have recently identified 4 protein biomarkers associated with
CMD evaluated by rubidium-82 positron emission tomography (PET)
in 97 patients [3]. In the present study we analyzed a range of CVD
biomarkers with the aim of identifying common internal patterns
representing pathophysiologic pathways which may be activated in
patients with CMD.2. Patients and methods
2.1. Enrollment, inclusion, baseline data
Participants with angina-like symptoms and no significant obstruc-
tive coronary artery disease (b50% coronary artery stenosis) were
enrolled betweenMarch 2012 and September 2014, according to the in-
clusion criteria for the iPOWER study [4] (see Supplemental materials).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
hagen from ClinicalKey.com by Elsevier on April 27, 2020.
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Abbreviations, alphabetical order
ACS acute coronary syndrome
BMI body mass index
CAD coronary artery disease
CFVR coronary flow velocity reserve
CMD coronary microvascular dysfunction
CVD cardiovascular disease
LoD limit of detection
MI myocardial infarction
PC principal component
PCA principal component analysis
PET positron emission tomography
Biomarkers
CCL2 C-C motif ligand 2
CCL15 C-C motif ligand 15
CCL16 C-C motif ligand 16
CHI3L1 Chinitase-3-like protein 1
CXCL16 C-X-C motif ligand 16
Gal4 Galectin-4
GDF15 growth differentiation factor 15
MMP-3 matrix metalloproteinase 3
MMP-9 matrix metalloproteinase 9
NTproBNP N-terminal prohormone of brain natriuretic peptide
PGLYRP1 peptidoglycan recognition protein 1
PON3 paraoxonase 3
SCGB3A2 secretoglobin family 3a member 2
suPAR soluble urokinase-type plasminogen activator receptor
TNF-α tumor necrosis factor α
TNFR1 tumor necrosis factor receptor 1
tPA tissue plasminogen activator
TRAIL TNF-related apoptosis-inducing ligand
2 J. Schroder et al. / IJC Heart & Vasculature 24 (2019) 100370A subgroup of the iPOWER cohort was randomly selected for protein
biomarker evaluation in this study.
2.2. Echocardiographic examination and coronary flow velocity reserve
measurements
All patients underwent coronary flow velocity reserve (CFVR)
measurement by transthoracic Doppler echocardiography of the left
anterior descending artery at rest and during maximum hyperemia
induced by dipyridamole infusion (0.84 mg/kg over 6 min) [5]. Left
ventricular ejection fractionwas analyzed by an experienced echocardi-
ographer using the GE EchoPac v. 112 automated biplane calculation
Auto-EF tool. For details regarding echocardiographic examination
specifics, please see the Supplemental materials.
2.3. Protein biomarkers
All blood samples were analyzed with the Olink cardiovascular
disease panel III (CVD III, Olink Proteomics, Uppsala, Sweden) using
Proximity Extension Assay technology, measuring 92 protein bio-
markers related to cardiovascular or other diseases by real-time
polymerase chain reaction (See Online Fig. 1 for biomarker list. See
Supplemental materials for a detailed description of the protein
biomarker analysis process) [6].
2.4. Statistical analyses
Baseline patient characteristics were analyzed for possible associations
with CFVR both as a continuous variable using linear regression andDownloaded for Anonymous User (n/a) at BS - University of Co
For personal use only. No other uses without permissiodichotomized (b2.5 and ≥2.5) using t-tests and χ2-tests for continuous
and categorical baseline variables, respectively.
The relation between each of the 92 protein biomarkers and the pri-
mary outcome, CFVR,was assessed using linear regression analysis after
plotting each biomarker against CFVR for possible non-linear associa-
tions. Model assumptions were assessed graphically for all biomarkers
and were best satisfied with log-2 transformed biomarker values
(covariate) and log-2 transformed CFVR values (outcome) [3]. Family-
wise error correction procedures (e.g. Bonferroni) or false discovery
rate correction were not possible to utilize due to the large number of
protein biomarkers and relatively small patient cohort (n = 174).
In an attempt to explore internal patterns within the group of pro-
tein biomarkers significantly associated with CFVR, a scaled principal
component analysis (PCA) was performed. Details of the procedure
are described in the Supplemental materials. Briefly, PCA is a statistical
tool for data exploration and simplification which enables reduction of
a larger number of variables into a smaller number of summary compo-
nents, while still retaining as much of the variance from the original
variables as possible [7]. In recent years PCA has been employed in
various fields of health research, e.g. for data exploration purposes and
development of clinical risk scores [8,9]. The PCA procedure may be
subdivided into 3 steps [10,11]:
i. Component extraction and selection: Significant protein bio-
marker internal correlations were examined by creating a
Pearson correlation matrix followed by calculation of Kaiser-
Meyer-Olkin measures and Bartlett's test statistic for sphericity.
The cut-off eigenvalue level was set conservatively at 1.2 to
avoid false discoveries. To simplify component interpretation,
no component rotation was employed.
ii. Interpretation of component loading structure: We determined a
threshold for component/variable loading N0.25 as meaningful for in-
terpretation i.e. a specific variable was considered to be associated
with a specific component if the loadingwas above this threshold [12].
iii. Computation and utilization of component scores: The loading coeffi-
cients were utilized to compute a separate component score for each
patient and each extracted component. The component scores were
then used to perform both univariate and multivariate adjusted
regression analyses for association between components and CFVR,
adjusting for the known risk factors for low CFVR which were found
to be significantly associated with CFVR in the present study:
Age, non-obstructive atherosclerosis in CAG, hypertension, diabetes
mellitus, smoking, body mass index (BMI) and total cholesterol [2].
To obtain a preliminary overview of the internal relations between
all protein biomarkers, an initial PCA including all 92 biomarkers
was also performed; however, due to the high number of protein bio-
markers relative to the cohort size the results were uninterpretable
and did not fulfillmethodological requirements of PCA. Further analyses
and post-estimations including all biomarkers were consequently
not conducted.
We assessed the predictive capability of the principal components
identified by fitting a logistic regression model to estimate the likeli-
hood of CMD defined as a binary classifier, with CFVRb2.0 designating
CMD. A basicmodel including age and all baseline variables significantly
related to CFVRwas compared to a model adding any significant princi-
ple components, and the difference in diagnostic ability was evaluated
using comparative receiver operating characteristics. Statin use was ad-
ditionally included in the logistic regression model to assess potential
anti-inflammatory effects related to statins.
Further, for the principal components which were significantly re-
lated to CFVR after multivariate adjustment, each individual biomarker
was also separately compared to the basic model, along with all bio-
markers which were related to CFVR in linear regression with p b 0.01.
All analyses were performed using STATA/IC 13.1 (StataCorp LP,
College Station, TX, USA).penhagen from ClinicalKey.com by Elsevier on April 27, 2020.
n. Copyright ©2020. Elsevier Inc. All rights reserved.
Table 2
Principal component analysis loading matrix.
Variable PC1 PC2 PC3
CCL15 0.244 −0.258 −0.016
CCL16 0.258 −0.227 0.054
CHI3L1 0.218 −0.088 −0.275
CHIT1 0.142 −0.043 0.100
CXCL16 0.291 −0.001 0.193
GDF15 0.277 −0.172 −0.135
Gal4 0.228 −0.257 −0.050
MMP3 0.247 0.017 0.280
MMP9 0.224 0.433 −0.290
NTproBNP 0.151 −0.285 0.120
PGLYRP1 0.253 0.314 −0.288
PON3 0.133 0.224 0.686
SCGB3A 0.150 0.347 0.188
ST2 0.252 −0.115 0.194
TNFR1 0.305 −0.038 −0.023
TNFRSF10C 0.254 0.258 −0.020
suPAR 0.294 0.249 −0.156
tPA 0.211 −0.301 −0.148
Eigenvalue 9.18 1.47 1.21
Total variance, % 51.04 8.18 6.73
Accumulative variance, % 51.04 59.22 65.95
Upper part: Loading scores for the 3 retained principal components. Lower part:
Eigenvalues and corresponding variance for the 3 components.
PC = principal component. Biomarker abbreviations as for Table 1. Bold highlights load-
ings N0.25.
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The studywas performed in accordancewith the Helsinki Declaration
and was approved by the Danish Regional Committee on Biomedical
Research Ethics (H-3-2012-005). All participants gave written informed
consent, after receiving oral and written information about the study.
3. Results
3.1. Study population
The study population consisted of 174 women with angina, median
age was 64 years (SD 9.8), median CFVR was 2.3 (IQR 1.9–2.7), and 28%
of patients had CFVR b 2.0. Patients with low CFVR more often had
diffuse atherosclerosis in the baseline coronary angiogram (p b 0.001)
and had more hypertension (p = 0.01) than patients with higher
CFVR, while no other baseline characteristics were associated with
CFVR (p N 0.05) (Online Fig. 2).
3.2. Biomarkers
95% of the measured proteins were detected in all 174 samples
(See Supplemental Materials). In univariate regression analysis, 18 of
the 92 protein biomarkers were significantly related to CFVR (Table 1).
3.3. PCA
Evaluation of the data structure generally supported the use of PCA:
The Pearson correlation matrix showed a large proportion of significant
correlations between the selected 18 biomarkers, and roughly half of
the correlation coefficients were N0.5 (Online Fig. 3). The Kaiser-
Meyer-Olkin measures of sampling adequacy were high (Online
Fig. 4), and Bartlett's test for sphericity was highly significant (chi2 b
0.001). In the initial PCA output, 3 components had eigenvalues N1.2,
supporting selection of 3 components for further loading structure
interpretation (Table 2).
The component loading structure was examined in a loading matrix
to assess biomarker loading patterns on the 3 selected components.
Differential loading (i.e. one variable loading significantly to more than
one component) was minimal (Table 2). The first component (PC1)
had loadings N0.25 for 8 biomarkers: C-C motif ligand 16 (CCL16), C-X-
C motif ligand 16 (CXCL16), growth differentiation factor 15 (GDF15),
peptidoglycan recognition protein 1 (PGLYRP1), ST2, tumor necrosis
factor receptor-1 (TNFR1), soluble urokinase-type plasminogen activator
receptor (suPAR) and tumor necrosis factor receptor superfamily mem-
ber 10C (TNFRSF10C); the second component (PC2) for 8 biomarkers:Table 1
Protein biomarkers significantly associated with CFVR.
Biomarker R p Value Biomarker R p Value
CCL15 −0.16 0.034 NTproBNP −0.16 0.036
CCL16 −0.15 0.046 PGLYRP1 −0.20 0.009
CHI3L1 −0.19 0.011 PON3 0.16 0.037
CHIT1 −0.18 0.020 SCGB3A −0.16 0.034
CXCL16 −0.17 0.029 ST2 −0.16 0.038
GDF15 −0.25 0.001 suPAR −0.23 0.003
Gal4 −0.17 0.026 TNFR1 −0.15 0.047
MMP3 −0.15 0.045 TNFRSF10C −0.19 0.012
MMP9 −0.24 0.002 tPA −0.16 0.036
Regression analysis results for the relation between significant biomarkers CFVR
value. R = Pearson correlation coefficient.
Biomarker abbreviations alphabetically: CCL15= C-C motif ligand 15, CCL16= C-C motif
ligand 16, CHI3L1 = Chinitase-3-like protein 1, CHIT1 = chitotriosidase, CXCL16 = C-X-C
motif ligand 16, GDF15 = growth differentiation factor 15, Gal4 = Galectin-4, MMP3 =
matrixmetalloproteinase 3,MMP9=matrixmetalloproteinase 9, NTproBNP=N-terminal
prohormone of brain natriuretic peptide, PGLYRP1 = peptidoglycan recognition protein 1,
PON3 = paraoxonase 3, SCGB3A = secretoglobin family 3a member 2, TNFR1 = tumor
necrosis factor receptor 1.
Downloaded for Anonymous User (n/a) at BS - University of Copen
For personal use only. No other uses without permission. CC-C motif ligand 15 (CCL15), galectin-4 (Gal4), MMP-9, N-terminal
prohormone of brain natriuretic peptide (NTproBNP), PGLYRP1,
secretoglobin family 3a member 2 (SCGB3A2), TNFRSF10C and tissue
plasminogen activator (tPA); and the third component (PC3) for 5 bio-
markers: Chinitase-3-like protein 1 (CHI3L1), matrix metalloproteinase
3 (MMP-3),MMP-9, PGLYRP1 and paraoxonase 3 (PON3). Total variance
explained by the 3 components was 66%.
The aggregate component scores calculated from the component
loading coefficients for each patient were significantly associated with
CFVR for PC1 (p= 0.002) and PC3 (p=0.009) in univariate regression
analysis, while PC2 showed no association with CFVR (p= 0.91). After
multivariate adjustment for CMD risk factors (Online Fig. 5) component
1 was still significantly related to CFVR (p= 0.04), while component 3
was not (p= 0.14).
Addition of PC1 scores to a multiple logistic regression model for
predicting CFVR b 2.0 did not significantly improve area under the
curve (0.67 vs 0.64, p= 0.22) (Fig. 1). Further addition of statin use to0.
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Fig. 1. Comparison of ROC curves Addition of PC1 to the ROC plot increased predictive
power (red curve), but this effect was not significant (p = 0.22). PC1 = principal
component 1.
hagen from ClinicalKey.com by Elsevier on April 27, 2020.
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4 J. Schroder et al. / IJC Heart & Vasculature 24 (2019) 100370the logistic regression model neither increased nor decreased the area
under the curve significantly (0.64 vs. 0.67, p= 0.24).
Individual addition of the PC1 related biomarkers and MMP-9 to the
basic model did not significantly improve the area under the curve
(Online Fig. 6).
4. Discussion
In this study investigating the relationship between a large number
of CVD protein biomarkers and CMD, 18 biomarkers were significantly
related to CFVR. We identified two principal components significantly
associated with CFVR. PC1 accounted for 51% of biomarker variance
and was significantly related to CFVR after multiple adjustment.
4.1. Principal component 1 protein biomarkers and inflammation
The 6 PC1 biomarkers CCL16, CXCL16, PGLYRP1, TNFR1, GDF15 and
TNFRSF10C all have direct or indirect associations with the interleukin
IL-1β – TNF-α – IL-6 – CRP inflammatory pathway and the pro-
inflammatory hypothesis of atherosclerotic development. This is
noteworthy in the light of past findings in CMD research which also
highlight this specific pathway [13,14]. In Fig. 2, an overview of
functional relationships between PC1 biomarkers and related proteins
are outlined graphically.
The chemokine C-C motif ligand 16 (CCL16) is upregulated in stress
conditions, and elicits its effects both as a direct chemoattractant forFig. 2. Principal component 1 biomarker overview Protein biomarker interactions and downstre
biomarkers in grey, highlighted with “PC1”marker. Other proteins and effectors in dark blue.
CFVR after multivariate adjustment. Black arrows indicate a stimulation or upregulation,
connection. CCL2 = C-C motif ligand 2, CRP = c-reactive protein, IL-1β= interleukin 1β, IL-
necrosis factor α, TRAIL = TNF-related apoptosis-inducing ligand. All other abbreviations as in
Downloaded for Anonymous User (n/a) at BS - University of Co
For personal use only. No other uses without permissiomonocytes and lymphocytes, and by activating themorewell described
chemokine C-C motif ligand 2 (CCL2) which has been implicated in
development of cardiac fibrosis, inflammation and hypertension in
animal models [15]. The related chemokine CXC ligand 16 (CXCL16)
also induces CCL2 release, butmore importantly CXCL16 is an important
inflammatory mediator in the IL-1β/TNF-α inflammatory pathway
in patients with atherosclerotic heart disease [16]. In CAD patients
blockage of IL-1β signaling directly inhibited CXCL16 release from pe-
ripheral blood monocytes [17]. CXCL16 is expressed in atherosclerotic
lesions in both humans and animal models and has also been proposed
as a mediator between inflammation and dyslipidemia in the athero-
sclerotic process due to increased foam cell formation resulting from
CXCL16 stimulation [18].
Peptidoglycan is a major constituent of most bacteria's cell wall,
and peptidoglycan recognition proteins (PGLYRPs) play an impor-
tant role both as direct bactericides and as inflammatory mediators.
Presence of PGLYRP1 has been demonstrated in human coronary
atheroma, stimulating production of the pro-inflammatory cyto-
kines interleukin-1/-6, TNF-α, CCL2 and metalloproteinases such
as MMP-9 [19]. Increased levels of PGLYRP1 were associated with
both increased coronary artery calcium and plaque burden in
the Dallas Heart Study of N3000 community dwelling individuals
[20]. In a subsequent follow-up study PGLYRP1 levels robustly
predicted a 3-fold increase in atherosclerotic CVD events, and this
association was strongest in patients with elevated hs-CRP levels.
Accordingly, PGLYRP1 has been proposed as a possible link betweenampathological effects. See “Discussion” for details and references. Principal component 1
Downstream effects in red. MMP-9 was not part of PC1, but was independently related to
red truncated connectors indicate inhibition. Red question mark indicates a possible
6 = interleukin 6, IL-33 = interleukin 33, ST2L = transmembrane ST2, TNFα= tumor
Table 1.
penhagen from ClinicalKey.com by Elsevier on April 27, 2020.
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ment of atherosclerosis.
While TNF-α itself was not featured in the present biomarker panel
due to technical restrictions in the applied assay, itsmain effector recep-
tor TNF receptor 1 (TNFR1) was significantly associated with CFVR and
showed high loading on PC1. Activation of TNFR1 produces extensive
downstream pro-inflammatory effects e.g. activation of IL-6 cascade
and nuclear factor kappa B [21]. Downstream harmful inflammatory
effects of TNFR1 stimulation have long been implicated in CADdevelop-
ment through alteration of vascular cell function [22]. TNFR1 activation
is also suggested to play a more short-acting role in the event of acute
coronary syndrome plaque instability, and elevated levels of TNF-α
and TNFR1 have been shown to predict coronary events in 1464
patients with chronic systolic heart failure [23]. A range of pathways
associated with TNF-α, TNFR1, IL-6 and IL-1β are being investigated
for possible therapeutic inhibition which may improve outcomes in
different groups of CVD patients [22,24], e.g. the TNF-α inhibitors
adalimumab and infliximab [25]. It has recently been demonstrated in
the CANTOS trial that monoclonal antibodies targeting interleukin-1β,
an upstream regulator of TNF-α, reduced first occurrence of major car-
diovascular events (myocardial infarction (MI), stroke and CV death)
compared with placebo in patients with previous MI [26].
TNF receptor superfamily 10C (TNFRSF10C) is also known as decoy
receptor 1, and TNF-related apoptosis-inducing ligand (TRAIL) is the
primary ligand for TNFRSF10C. The main known effect of TRAIL is to
induce apoptosis via binding to death receptors, but binding of TRAIL
to TNFRSF10C conversely attenuates the apoptotic actions of TRAIL via
sequestering [27]. The exact role of TNFRSF10C is largely unknown,
but it may be speculated that a general inflammatory activation in
CMD patients also upregulates balancing proteins such as TNFRSF10C,
which in turn may moderate the cascade responses of the pro-
inflammatory pathways.
Growth differentiation factor 15 (GDF15) is a further inflammatory
biomarker which showed loading on PC1. It has been intensively stud-
ied in recent years as a strong and robust predictor of all-cause mortal-
ity, and adverse cancer and CVD outcomes [28]. GDF15 synthesis is
stimulated by TNF-α, but at the same time it may also serve as a para-
crine negative feedback inhibitor of TNF-α release which moderates
the TNF-α cascade. GDF15 is highly expressed by macrophages in ath-
erosclerotic lesions, and GDF15 has shown promise as a new, robust
predictor for adverse CVD outcomes in large observational cohorts and
clinical trials such as STABILITY and PLATO [29,30].
Past biomarker studies in patients with CMD have also implicated
TNF-α, IL-6 and hs-CRP as possible pathogenetic determinants: A study
of 86 obese patients found IL-6 and TNF-α to be significantly associated
with CMD (p b 0.03 for both) [14], and in a small population of cardiac
syndrome X patients hs-CRP was significantly associated with CMD
(p = 0.001) [13].
4.1.1. ST2
ST2 is also known as interleukin-1 receptor-like 1 and exists in a
membrane bound receptor form (ST2L) and a soluble form (sST2); the
latter was measured in the present study and found to load on PC1.
The ligand for both forms is interleukin-33 (IL-33), and in a number of
experimental studies myocardial mechanical stress and hypoxia have
been shown to upregulate the expression of both IL-33 and ST2L,
resulting in cardioprotective effects such as reduction of cardiomyocyte
hypertrophy, prevention of hypoxia-related apoptosis and reduced
mortality; the soluble form sST2, on the other hand, sequesters IL-33
thereby decreasing activation of membrane bound ST2L and conse-
quently reducing the given cardioprotective effects (Fig. 2) [31]. While
IL-33 significantly reduced atherosclerotic plaque size in experimental
models of atherosclerosis, addition of sST2 directly counteracted this
effect and resulted in increased plaque size [32]. These findings have
motivated numerous studies examining the potential of sST2 as a
risk marker in patients with heart failure, acute coronary syndromeDownloaded for Anonymous User (n/a) at BS - University of Copen
For personal use only. No other uses without permission. C(ACS) and stable CAD [33,34], persistently demonstrating sST2 as a
robust prognostic biomarker of CVD outcomes. Therapeutic trials with
sST2-inhibiting antibodies have been shown to reduce graft versus
host disease severity and mortality, while sST2-inhibition remains to
be investigated in CVD.
4.1.2. Soluble urokinase-type plasminogen activator receptor (suPAR)
SuPAR loaded on PC1, and was also highly significantly related to
CFVR as a separate biomarker (p = 0.003). Increased suPAR levels
reflect low grade inflammation and have been linked to the early
stages of atherosclerotic development and subclinical organ damage
[35]. SuPAR has previously been linked to CMD assessed by
intracoronary Doppler flow measurement of CMD in 66 patients
with non-obstructive coronary atherosclerosis, where a higher
level of suPAR remained significantly associated with a lower CFVR
after multivariate adjustment (p = 0.04) [36]. SuPAR level was
further related to the presence of CAD and CVD outcomes in N3000
patients with suspected CAD, and addition of suPAR improved the
C-statistic significantly compared to a model based on traditional
risk factors [37].
4.1.3. Common features of PC1 related biomarkers
Most of the 8 protein biomarkers with high loadings on PC1 are
related to inflammatory pathways, either as upstream regulators,
downstream protein products expressing a pro-inflammatory state,
or parallel and moderating messenger pathways (Fig. 2). A majority of
the biomarkers have connection with the important IL-1β - TNF-α –
IL-6 – CRP inflammatory activation pathway, and inflammatory bio-
markers such as GDF15, ST2 and suPAR are increasingly discussed as
promising future risk stratification biomarkers in both stable CAD, ACS
and heart failure. The concept of prolonged low-grade subclinical in-
flammation as a pivotal component in the development of CVD is not
new [38], but in recent years evidence supporting the inflammatory hy-
pothesis has been gathering [39]. This is further supported by biomarker
studies which have helped introduce potential upstream proteins avail-
able for targeted treatment interventions. Several studies are evaluating
different immunomodulation strategies in CVD [25,26], yet no such
interventional trials have been undertaken in the field of CMD. The cur-
rent study suggests that the well-known association between inflam-
mation and macrovascular CVD may also pertain to presence of CMD,
i.e. inflammation may be a common pathogenetic factor in both
macro- and microvascular disease.
Addition of PC1 to a standard risk factor based prediction model did
not significantly improve the area under the curve. Consequently, the
PCA results are not readily translatable to diagnostic implementation,
and should be interpreted as hypothesis generating. Lack of enhance-
ment of predictive power after adding a biomarker to standard risk fac-
tors has also been described for a majority of CVD biomarkers in past,
larger studies. This finding has been attributed to a possible role of bio-
markers as mediating or co-incident factors, rather than entities
representing independent increases in patient risk [40,41].
4.2. Other protein biomarkers
MMP-9 had a strong association with CFVR (p= 0.002) and is also
activated by PGLYRP1whichwas part of PC1.Matrixmetalloproteinases
(MMPs) are important in normal degradation of collagen in the extra-
cellular matrix and migration of neutrophil granulocytes across the
basement membrane. Following stress such as MI, MMPs are activated
by pro-inflammatory cytokines resulting in increased breakdown of
the cardiomyocyte collagen skeleton which otherwise ensures normal
structure, thereby contributing to post-ischemic ventricular dilatation
[42]. MMP-9 has been studied in relation to development of heart fail-
ure,whereMMP-9 levelswere associatedwith increased left ventricular
diastolic dimensions and wall thickness in 699 patients with previous
MI [43]. MMP-9 has also shown potential as a general CAD risk marker,hagen from ClinicalKey.com by Elsevier on April 27, 2020.
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MMP-9's direct involvement in heart failure remodeling and cytokine
activation has given rise to interventional trials with the nonspecific
MMP inhibitor doxycycline, effectively blocking MMP-9 activities and
attenuating myocardial fibrosis and adverse LV remodeling [45].
In a previous, smaller study by our group investigating possible asso-
ciations between the CVD III biomarker panel and CMD evaluated with
PET, 4 biomarkers were significantly associated with CMD, 3 of which
(GDF15, tPA, Gal4) were also significant in the present study [3].
Inter-study differences may conceivably be ascribed to smaller popula-
tion size, different examination modalities and random variation. Few
other studies have investigated biomarkers in small CMD populations:
One study found increased activation of circulating progenitor cells
related to CMD in 123 women [46], while a study by Bozcali et al. in
115 cardiac syndrome X patients found higher levels of the inflamma-
tion and fibrosis biomarker galectin-3 (Gal3) compared with healthy
controls [47]. In the present study, there was no significant relation
between Gal3 and CFVR.
4.3. Study strengths and limitations
To date only few studies have examined protein biomarkers in CMD,
and they have mainly evaluated individual biomarkers in small patient
populations. The present study is the first to evaluate a large-scale bio-
marker panel in relation to CMD. Further, we attempt to uncover new
internal patterns of CMD-related biomarkers through the utilization of
PCA statistics, which is an apt approach for identification of underlying
patterns in large data sets.
Although the present study is fairly large in the context of CMD
research, themain limitation is nonetheless the relatively small popula-
tion sample size in relation to thewide range of biomarkers represented
in the used assay. As noted, strict adjustment of p-values for multiple
comparisons was not possible due to population size (risk of type II
error), and this in turn naturally introduces a risk of type I error in the
initial separate regression analyses. Accordingly, our findings should
be interpreted as hypothesis generating; however, the use of PCA
and subsequent review of available evidence support the notion that a
considerable proportion of the identified correlations are not mere
chance findings, since 18 out of 92 biomarkers were related to CFVR,
and the identified PC1 biomarkers share roles in common inflammatory
pathways.
Themethod used for inducingmaximum hyperemia by dipyridamole
infusion mainly evaluates non-endothelium dependent vasodilatation.
Results are not comparable to coronary vascular function assessed by
e.g. acetylcholine provocation.
All studied patients were female, and it is therefore unknown
whether the results would be different in a cohort including male
angina patients.
4.4. Conclusion
We identified 18 protein biomarkers significantly associated with
impaired microvascular dilatation in women with angina but no signif-
icant CAD. We further identified 8 biomarkers with common loading
on a principal component significantly associated with CMD after mul-
tiple adjustment, most of which were related to the TNF-α – IL-6
pro-inflammatory pathway.
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